NCT00417209 - Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen | Biotech Hunter

Enrollment

408

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

July 31, 2009

Study Completion Date

November 30, 2009

Conditions

Pancreatic Neoplasms

Interventions

DRUG

Larotaxel (XRP9881)

administered as a 1-hour IV infusion on Day 1 of every 3 weeks (q3w)

DRUG

5-Fluorouracil

administered as IV infusion from Day 1 to Day 4

DRUG

Capecitabine

administered orally from Day 1 to Day 14 q3w

Trial Locations (21)

Sanofi-Aventis Administrative Office, Bridgewater

Sanofi-Aventis Administrative Office, Diegem

Sanofi-Aventis Administrative Office, São Paulo

Sanofi-Aventis Administrative Office, Laval, Quebec

Sanofi-Aventis Administrative Office, Santiago

Sanofi-Aventis Administrative Office, Bogotá

Sanofi-Aventis Administrative Office, Prague

Sanofi-Aventis Administrative Office, Helsinki

Sanofi-Aventis Administrative Office, Berlin

Sanofi-Aventis Administrative Office, Budapest

Sanofi-Aventis Administrative Office, Mumbai

Sanofi-Aventis Administrative Office, Milan

Sanofi-Aventis Administrative Office, México

Sanofi-Aventis Administrative Office, Lysaker

Sanofi-Aventis Administrative Office, Lima

Sanofi-Aventis Administrative Office, Warsaw

Sanofi-Aventis Administrative Office, Moscow

Sanofi-Aventis Administrative Office, Brastislava

Sanofi-Aventis Administrative Office, Madrid

Sanofi-Aventis Administrative Office, Istanbul

Sanofi-Aventis Administrative Office, Guildford, Surrey